Kazia Therapeutics Secures $46.5 Million Through Private Placement to Address Nasdaq Compliance

Kazia Therapeutics ( (KZIA) ) has issued an announcement.

On December 2, 2025, Kazia Therapeutics Limited entered into Securities Purchase Agreements with institutional and accredited purchasers for a private placement of equity securities, raising approximately $46.5 million. This financial move was aimed at addressing the company’s compliance with Nasdaq’s listing standards, following a staff determination letter received on November 12, 2025, indicating the company’s market value was below the required minimum. The successful private placement is expected to enhance Kazia’s stockholders’ equity, potentially aiding in regaining compliance with Nasdaq’s requirements, although there is no guarantee of the outcome.

The most recent analyst rating on (KZIA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.

Spark’s Take on KZIA Stock

According to Spark, TipRanks’ AI Analyst, KZIA is a Underperform.

Kazia Therapeutics has a low overall stock score due to significant financial instability marked by declining revenues, negative equity, and cash flow issues. Technical indicators suggest bearish momentum, and poor valuation metrics reflect the company’s unprofitability. The absence of dividends and positive earnings call or corporate events data further emphasize the company’s challenges.

To see Spark’s full report on KZIA stock, click here.

More about Kazia Therapeutics

Kazia Therapeutics Limited is a biotechnology company focused on the development of innovative anti-cancer drugs. The company operates in the pharmaceutical industry, primarily targeting the oncology market with its pipeline of therapeutic candidates.

Average Trading Volume: 730,977

Technical Sentiment Signal: Hold

Current Market Cap: $22.35M

For detailed information about KZIA stock, go to TipRanks’ Stock Analysis page.